Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study

R Dummer, P Queirolo, PG Duhard, Y Hu… - The Lancet …, 2023 - thelancet.com
Background Targeted therapy and immunotherapy have shown intracranial activity in
melanoma with CNS metastases, but there remains an unmet need, particularly for patients …
被引用次数：18 相关文章

Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study

R Dummer, P Queirolo, PG Duhard, Y Hu, D Wang… - The Lancet …, 2023 - Elsevier
Background Targeted therapy and immunotherapy have shown intracranial activity in
melanoma with CNS metastases, but there remains an unmet need, particularly for patients …

Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.

R Dummer, P Queirolo, G Duhard, Y Hu… - The Lancet …, 2023 - europepmc.org
Background Targeted therapy and immunotherapy have shown intracranial activity in
melanoma with CNS metastases, but there remains an unmet need, particularly for patients …

Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study

R Dummer, P Queirolo, PG Duhard… - The Lancet …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Targeted therapy and immunotherapy have shown intracranial activity in
melanoma with CNS metastases, but there remains an unmet need, particularly for patients …

Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study

R Dummer, P Queirolo, PG Duhard… - The lancet …, 2023 - mdanderson.elsevierpure.com
Background: Targeted therapy and immunotherapy have shown intracranial activity in
melanoma with CNS metastases, but there remains an unmet need, particularly for patients …

Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study

R Dummer, P Queirolo, PG Duhard, Y Hu… - The Lancet …, 2023 - thelancet.com
Background Targeted therapy and immunotherapy have shown intracranial activity in
melanoma with CNS metastases, but there remains an unmet need, particularly for patients …